Stage IV Rectal Cancer with Liver Metastases: Is There a Benefit to Resection of the Primary Tumor?

被引:23
作者
Cellini, Christina [1 ]
Hunt, Steven R. [1 ]
Fleshman, James W. [1 ]
Birnbaum, Elisa H. [1 ]
Bierhals, Andrew J. [2 ]
Mutch, Matthew G. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Surg, Sect Colon & Rectal Surg, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
关键词
COLORECTAL-CANCER; NONOPERATIVE MANAGEMENT; PALLIATIVE RESECTION; SURGICAL RESECTION; CHEMOTHERAPY; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; IRINOTECAN; COMBINATION;
D O I
10.1007/s00268-010-0483-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
Resection of primary and liver lesions is the optimal management of Stage IV rectal cancer with liver metastases. For patients with extensive liver metastases, FOLFOX and FOLFIRI have improved resection rates and survival. We compared survival outcomes in patients with Stage IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all. Patients with metastatic rectal cancer to liver were identified from a colorectal cancer database from 2002 to 2008. Patients received neoadjuvant chemoradiation and adjuvant FOLFOX or FOLFIRI therapy. The outcomes for patients who underwent synchronous resection, staged resection, resection of rectal tumor only, and no resection with chemotherapy only were compared. Statistical analysis was determined by ANOVA. Survival was determined using the Kaplan-Meier method. Seventy-four patients were identified: 30 synchronous resections, 13 staged resections, 22 primary resection only, and 9 no resection. Median follow-up was 23 months (range = 4-58 months). Sixty-five percent of patients underwent liver resection with 26% rendered eligible for resection after adjuvant therapy. Those who underwent primary resection only had shorter median survival than those who underwent either staged or synchronous liver resection (31 vs. 47 vs. 46 months, respectively; P = 0.17). Survival was no different for synchronous versus staged resection (P = 0.6). Volume of liver disease predicted resectability (P = 0.001). Without liver resection, 2-year survival was approximately 60%. Palliative surgery was required in six of nine patients who did not undergo resection of their primary tumor. Current chemotherapeutic regimens lead to improved survival in patients with unresectable liver metastases. Upfront chemotherapy in the asymptomatic patient compared with resection of the primary tumor does not appear to significantly affect survival. However, given that 60% of patients were alive after 2 years, resection of the primary lesion for palliative reasons and local control must be considered.
引用
收藏
页码:1102 / 1108
页数:7
相关论文
共 27 条
[1]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[2]   Is palliative resection of the primary tumour, in the presence of advanced rectal cancer, a safe and useful technique for symptom control? [J].
Al-Sanea, N ;
Isbister, WH .
ANZ JOURNAL OF SURGERY, 2004, 74 (04) :229-232
[3]   Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials [J].
Arkenau, Hendrik-Tobias ;
Arnold, Dirk ;
Cassidy, Jim ;
Diaz-Rubio, Eduardo ;
Douillard, Jean-Yves ;
Hochster, Howard ;
Martoni, Andrea ;
Grothey, Axel ;
Hinke, Axel ;
Schmiegel, Wolff ;
Schmoll, Hans-Joachim ;
Porschen, Rainer .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5910-5917
[4]   Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J].
Bismuth, H ;
Adam, R ;
Levi, F ;
Farabos, C ;
Waechter, F ;
Castaing, D ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1996, 224 (04) :509-520
[5]   Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: An analysis of surveillance, epidemiology, and end results data, 1988 to 2000 [J].
Cook, AD ;
Single, R ;
McCahill, LE .
ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (08) :637-645
[6]   Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review [J].
Eisenberger, Andrew ;
Whelan, R. Lawrence ;
Neugut, Alfred I. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (06) :559-568
[7]   A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
[8]   Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].
Grothey, A ;
Sargent, D ;
Goldberg, RM ;
Schmoll, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214
[9]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[10]   PALLIATIVE RESECTION FOR COLORECTAL-CARCINOMA [J].
JOFFE, J ;
GORDON, PH .
DISEASES OF THE COLON & RECTUM, 1981, 24 (05) :355-360